Form 497VPU LINCOLN LIFE VARIABLE
THE LINCOLN NATIONAL LIFE INSURANCE COMPANY
Lincoln Life Variable Annuity Account N
Lincoln ChoicePlusSM, Lincoln ChoicePlusSM II, Lincoln
ChoicePlus AssuranceSM (B-Share)
Lincoln ChoicePlusSM Access, Lincoln ChoicePlusSM II Access, Lincoln
ChoicePlus AssuranceSM (C-Share)
Lincoln ChoicePlusSM II Advance, Lincoln ChoicePlus AssuranceSM (L-Share)
Lincoln ChoicePlus AssuranceSM (A-Share), Lincoln ChoicePlusSM Advisory
Lincoln ChoicePlusSM Design, Lincoln ChoicePlusSM Rollover, Lincoln
ChoicePlusSM Signature
Lincoln ChoicePlus AssuranceSM Series, Lincoln ChoicePlus AssuranceSM (Prime)
Lincoln InvestmentSolutionsSM RIA
Prospectus Supplement dated November 10, 2025 to the
Updating Summary Prospectus for Current Contractowners dated May 1, 2025
This supplement discusses changes to your variable annuity summary prospectus. All other provisions in your prospectus, as supplemented, remain unchanged.
Benefits Available Under Your Contract – Living Benefit Riders.
Beginning February 17, 2026, the following options of the Lincoln ProtectedPay® Lifetime Income Suite will no longer be available for election by any
contractowner (including existing contractowners):
|
•
|
Lincoln ProtectedPay Secure Core®
|
|
•
|
Lincoln ProtectedPay Secure Core® and Estate LockSM
|
|
•
|
Lincoln ProtectedPay Secure Plus®
|
|
•
|
Lincoln ProtectedPay Secure Max®
|
Additionally, beginning February 17, 2026, i4LIFE® Advantage Guaranteed Income Benefit (Managed Risk) is only available if you are transitioning from a
Prior Rider.
Please note that all riders discussed in this supplement may not be available under your contract. You can obtain additional information by contacting your registered representative, online at www.lfg.com/vaprospectus, or by
sending an email request to [email protected].
Please retain this supplement for future reference.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Start of Day Message
- Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
- Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share